Loading
A phase 2 trial in lung cancer, run by Jiangsu Alphamab Biopharmaceuticals Co., Ltd, not yet recruiting.
A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer is a phase 2, interventional study registered as NCT07283198 by Jiangsu Alphamab Biopharmaceuticals Co., Ltd, with a registry enrolment figure of 160 participants, started 2025-12-10 and due to reach its primary completion in 2027-08-30. Interventions recorded: JSKN033 Injection. Conditions listed: Non Small Cell Lung Cancer (NSCLC). Primary outcome: Number and Severity of Treatment-emergent Adverse Events (TEAEs); Objective response rate (ORR). Lung eligibility wording from the registry: "Histologically or cytologically confirmed locally advanced or metastatic NSCLC (per AJCC 8th Edition Lung Cancer TNM Staging) that is not eligible for curative surgery and/or curative radiotherapy". No results are recorded here; the registry entry is the source.
Shares Alphamab Oncology, Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.